NCT05262387View on ClinicalTrials.gov

A Study of LY900014 (Lyumjev) Versus Insulin Lispro (Humalog) in Participants With Type 1 Diabetes

PHASE1CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

February 14, 2022

Primary Completion Date

March 7, 2023

Study Completion Date

March 7, 2023

Conditions
Diabetes Mellitus, Type 1
Interventions
DRUG

Lyumjev with 50% basal rate reduction

Administered SC.

DRUG

Humalog with 50% basal rate reduction

Administered SC.

DRUG

Humalog with 100% basal rate reduction

Administered SC.

DRUG

Lyumjev with 100% basal rate reduction

Administered SC.

Trial Locations (1)

M4G 3E8

LMC Clinical Research Inc. (Bayview), Toronto

All Listed Sponsors
lead

Eli Lilly and Company

INDUSTRY